Regeneron expects $100M pre-tax IPR&D charge in Q3 2023 from Alnylam milestone

REGENERON PHARMACEUTICALS, INC.

Acquired IPR&D charge of $100M pre-tax due to clinical milestone for ALN-APP Alzheimer's program.
Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.78 in Q3 2023.
Milestone relates to collaboration with Alnylam Pharmaceuticals (ALNY) for early-onset Alzheimer's therapy.
Results for Q3 not finalized; actual amounts may differ from preliminary estimates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.